Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Hepcidin
Overview
Hepcidin is a 25-amino acid endogenous peptide hormone produced primarily by hepatocytes that serves as the master regulator of systemic iron homeostasis. It binds to ferroportin, the sole known cellular iron exporter, inducing its internalization and degradation, thereby blocking iron release from enterocytes, macrophages, and hepatocytes.
Mechanism of Action
Therapeutic hepcidin agonists and antagonists are being developed to treat iron overload disorders and anemia of chronic disease, respectively.
Research Summary & Key Findings
Hepcidin was first characterized in 2001 (Blood, JCI) as a key iron regulatory hormone. Multiple hepcidin mimetics and antagonists have entered Phase 1 and Phase 2 clinical trials for conditions including beta-thalassemia, polycythemia vera, and anemia of chronic kidney disease, though none have yet achieved regulatory approval.
Clinical Status
Hepcidin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Hepcidin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Hepcidin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Hepcidin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hematology
Bivalirudin (Angiomax)
FDA ApprovedA synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and...
View detailsRomiplostim (Nplate)
FDA ApprovedA thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an...
View detailsPegcetacoplan (Empaveli)
FDA ApprovedA pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pa...
View detailsPeginesatide (Omontys)
FDA ApprovedPeginesatide is a synthetic pegylated peptide-based erythropoiesis-stimulating agent (ESA) consisting of two 21-amino ac...
View detailsNo lawful pathway today
Hepcidin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.